Expression of bone sialoprotein in prostate cancer and its clinical significance

Abstract

Objective To investigate the expression of bone sialoprotein (BSP) in prostate cancer and its clinical significance. Methods Prostate cancer tissues of different pathological grades (68 cases) and benign prostatic hyperplasia tissues (22 cases) were selected. SP method was used to detect the expression of BSP. Serum total prostate-specific antigen (tPSA) levels of prostate cancer were detected by electrochemiluminescence immunoassay before the operation. Results Compared with no or low expression in the adjacent normal glandular tissues, the detectable levels of BSP were examined in most of the prostate cancer tissues. The expression rate of BSP in prostate cancer tissues was higher than that in benign prostatic hyperplasia tissues [76.47 % (52/68) vs 13.64 % (3/22), χ2 = 27.614, P< 0.001]. The expression rates of BSP in well differentiated, moderately differentiated and poorly differentiated tissues according to cell differentiating degree (Gleason system) were 75.0 % (12/16), 77.5 % (31/40) and 75.0 % (9/12) respectively. There was no significant difference in various pathological grading (χ2 = 0.057, P= 0.972). The expression rates of BSP in pathological stage pT2, pT3 and pT4 tissues were 62.16 % (23/37), 95.24 % (20/21) and 90.0 % (9/10) respectively. A statistically significant association was found between BSP expression and pathological stage (χ2 = 9.338, P= 0.009). Serum tPSA level of prostate cancer group with BSP expression was higher than that with no BSP expression [(69.06±25.52) μg/L vs (38.00±21.64) μg/L, F= 19.355, P< 0.001]. Conclusion The high expression of BSP in prostate cancer has a relationship with pathological stage and serum tPSA level, it may play an important role in the biological behaviour of prostate cancer. Key words: Prostatic neoplasms; Bone sialoprotein; Prostate-specific antigen; Immunohistochemistry